Hepcidin may differentiate between types of anaemia, which may lead to varied therapeutic strategies, according to new research. Authors suggest that hepcidin may be more effective as a diagnostic marker of anaemia in cancer patients than serum iron, total iron-binding capacity (TIBC), or transferrin saturation (TSAT). They state that hepcidin could be used as a serological marker in the differential diagnosis of tumour-related anaemia of chronic disease (ACD) and iron deficiency anaemia.
Ironresource.org is a non-promotional, educational resource exclusively available to healthcare professionals working in iron therapy from a host of therapeutic areas.
Ironresource.org is an educational programme funded by Vifor (International) Inc. All content is independently generated by the Ironresource.org faculty experts reflecting their knowledge and opinions.